Mark D. Anderson

Mark D. Anderson, MD is an Associate Professor in the Department of Neurology at the University of Mississippi Medical Center's School of Medicine. Board certified in Neurology by the American Board of Psychiatry and Neurology and in Neuro-Oncology by the United Council of Neurologic Subspecialties, he serves on the Cancer Institute Clinical Leadership Committee and co-chairs the Multidisciplinary Tumor Board for CNS tumors.

Education:

• MD in Medicine, University of Alabama-Birmingham (2007)
• BS and MS in Biomedical Engineering, University of Miami (2003)
• Neuro-Oncology Fellowship, The University of Texas M.D. Anderson Cancer Center
• Neurology Residency, Vanderbilt University

Dr. Anderson's research centers on neuro-oncology with emphasis on central nervous system tumors, glioblastoma therapeutics, and cancer-related neurological complications. His clinical work focuses on tumor board leadership and developing targeted therapies for malignant brain tumors, particularly investigating drug delivery systems for glioblastoma treatment. He actively contributes to understanding viral complications in neuro-oncology patients and rare tumor pathologies.

His publication record (2013-2018) demonstrates sustained focus on neuro-oncology, with recurring themes in glioma biology, treatment resistance mechanisms (particularly bevacizumab discontinuation), viral interactions with brain tumors, and molecular diagnostics including IDH1 mutation analysis. The research spans clinical case reports, therapeutic studies, and molecular investigations across CNS tumor types.

Grants and Advising:

• Principal Investigator: NCI-funded study Toward Changing Glioblastoma Outcomes (2018-2020) on targeted drug delivery systems
• Neurology Residency Advisor since 2018
• Regular lecturer on CNS tumors for Cancer Registrars and Mississippi Neurosurgical Society

Dr. Anderson co-chairs the CNS Multidisciplinary Tumor Board and serves on multiple cancer committee panels, integrating clinical care with research protocols through the UMMC Cancer Institute. His work bridges laboratory findings with clinical applications in neuro-oncology practice.